FDA Approves the First Generic of Climara Pro, a Once-Weekly Estradiol-Levonorgestrel Patch
The FDA approved Zydus's generic on Oct. 19 for women with an intact uterus, for menopausal vasomotor symptoms and osteoporosis prevention. The agency gave no price or launch date, and the brand label still carries the full boxed warning.
The Food and Drug Administration approved the first generic of Climara Pro, a once-weekly estradiol and levonorgestrel patch for menopausal hormone therapy, on Oct. 19 and announced it on Oct. 20.
The approval went to Zydus Pharmaceuticals (USA), according to the FDA's news release. Climara Pro is a Bayer brand. The FDA rated the generic therapeutically equivalent, so pharmacies can substitute it where state law allows. The agency gave no launch date or price and said to contact the manufacturer about availability.
What is the patch approved to treat?
The patch delivers 0.045 mg of estradiol and 0.015 mg of levonorgestrel per day and is applied once a week. It is indicated for women with an intact uterus for moderate to severe vasomotor symptoms of menopause and for prevention of postmenopausal osteoporosis, the FDA said. The progestogen is there to reduce the risk of endometrial hyperplasia from estrogen alone, which is why the product is not meant for women without a uterus.
The brand's prescribing information on DailyMed tells prescribers to start at the lowest effective dose for the shortest duration consistent with treatment goals and to attempt discontinuation at 3- to 6-month intervals. When the goal is only osteoporosis prevention, it says to consider non-estrogen medications first.
What does the label warn about?
The FDA release lists contraindications including undiagnosed abnormal genital bleeding, current or past breast cancer, estrogen-dependent neoplasia, active or past deep vein thrombosis, pulmonary embolism or arterial thromboembolic disease, hepatic impairment or disease, and protein C, protein S or antithrombin deficiency or other thrombophilic disorders. The most common adverse reactions, at 5 percent or more, include application site reaction, vaginal bleeding, breast pain, headache and back pain.
The Climara Pro label posted on DailyMed, revised March 2023, still carries the full class boxed warning for cardiovascular disorders, probable dementia, breast cancer and endometrial cancer. That matters because the FDA has been removing cardiovascular, breast cancer and dementia language from some hormone therapy labels since late 2025. A generic follows its brand's labeling, so check the current prescribing information before counseling from memory.
A generic changes the price and availability conversation, not the risk-benefit conversation. The same indication, contraindications and boxed warning apply.
What did the FDA say?
“Menopause is a universal experience for women, and it can greatly affect a person's quality of life. This approval makes effective treatment more accessible,” said Acting FDA Commissioner Kyle Diamantas in the release. Michael Davis, MD, PhD, director of the Center for Drug Evaluation and Research, said a patch “offers a convenient alternative to daily oral medications, which may help patients stay on track with their treatment.”
What it means in clinic
For patients on brand Climara Pro, expect pharmacy substitution once the generic ships, and tell billing staff to watch for formulary tier changes. A patient moving from an estrogen-only patch needs a reason to add a progestogen, namely an intact uterus; patients who have had a hysterectomy are outside this indication.
For the background on how the FDA has been rewriting hormone therapy warnings, see our interview with Dr. David Borenstein.
Reported, fact-checked and edited by The Script Pad's editorial staff.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
